

08/03/2004

1449

09896874

Sheet 1 of 1

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.


01-1693-N

Serial No.

09/896,874

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)



RECEIVED

JAN 31 2003

Applicant:

Fang et al.

TECH CENTER 1800/29

Filing Date:

June 29, 2001

Group:

1621

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
SC	WO 99/65870	23 Dec 1999	PCT				
SC	WO 96/22287	25 Jul 1996	PCT				
SC	EP 0,432,694	19 Jun 1991	Europe				X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

SC	Chevallier N. et al., Cathepsin D displays in vitro $\beta$ -secretase-like specificity, Brain Research 750 (1997), pages 11-19
SC	Kick E.K. et al., Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D, Chemistry and Biology, April 1997, 4: 297-307
SC	Ng J.S. et al., A practical synthesis of an HIV protease inhibitor intermediate - Diastereoselective epoxide formation from chiral $\alpha$ -aminoaldehydes, Tetrahedron Vol 51, No 23, pages 6397-6410, 1995

EXAMINER

S. Kumar

DATE CONSIDERED

3/31/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

04/03/2003



#10 1621

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(MBHB Case No. 01-1693-N)

In re Application of:

Fang et al.

Serial No.: 09/896,874

Filed: June 29, 2001

For: COMPOUNDS TO TREAT  
ALZHEIMER'S DISEASE

Group Art Unit: 1621

Examiner: Shailendra Kumar

**TRANSMITTAL LETTER**

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

JAN 31 2003


TECH CENTER 1600/2900

In regard to the above-identified patent application:

1. We are transmitting herewith the attached:
  - a) Transmittal Letter in Duplicate;
  - b) Supplemental Information Disclosure Statement
  - c) PTO Form 1449; and
  - d) Six Cited References.
2. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayments to the Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
3. CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service, with sufficient postage as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on January 24, 2003.

Respectfully submitted,

Steven J. Sarussi  
Reg. No. 32,784



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(MBHB Case No. 01-1693-N)

In re Application of:

Fang et al.

Serial No.: 09/896,874

Filed: June 29, 2001

For: COMPOUNDS TO TREAT  
ALZHEIMER'S DISEASE

Group Art Unit: 1621

Examiner: Shailendra Kumar

RECEIVED

JAN 31 2003

TRANSMITTAL LETTER

Commissioner for Patents  
Washington, D.C. 20231

TECH CENTER 1600/2900

In regard to the above-identified patent application:

1. We are transmitting herewith the attached:
  - a) Transmittal Letter in Duplicate;
  - b) Supplemental Information Disclosure Statement
  - c) PTO Form 1449; and
  - d) Six Cited References.
2. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayments to the Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
3. CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service, with sufficient postage as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on January 24, 2003.

Respectfully submitted,

Steven J. Sarussi  
Reg. No. 32,784